Arvee Laboratories (India) Limited (ARVEE) - Total Liabilities

Latest as of September 2025: Rs91.40 Million INR ≈ $988.48K USD

Based on the latest financial reports, Arvee Laboratories (India) Limited (ARVEE) has total liabilities worth Rs91.40 Million INR (≈ $988.48K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Arvee Laboratories (India) Limited - Total Liabilities Trend (2013–2025)

This chart illustrates how Arvee Laboratories (India) Limited's total liabilities have evolved over time, based on quarterly financial data. See ARVEE net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Arvee Laboratories (India) Limited Competitors by Total Liabilities

The table below lists competitors of Arvee Laboratories (India) Limited ranked by their total liabilities.

Company Country Total Liabilities
Sensei Biotherapeutics Inc
NASDAQ:SNSE
USA $14.19 Million
Maisons du Monde SAS
PA:MDM
France €1.06 Billion
Haily Group Bhd
KLSE:0237
Malaysia RM131.88 Million
Law Debenture Corp
LSE:LWDB
UK GBX191.35 Million
SKY E&M Co. Ltd
KQ:131100
Korea ₩25.99 Billion
Orbital Corporation Ltd
AU:OEC
Australia AU$8.85 Million
Caldwell Partners International Inc
TO:CWL
Canada CA$36.43 Million
BMG Resources Ltd
AU:BMG
Australia AU$76.70K

Liability Composition Analysis (2013–2025)

This chart breaks down Arvee Laboratories (India) Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ARVEE stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.52 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.29 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.23 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Arvee Laboratories (India) Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Arvee Laboratories (India) Limited (2013–2025)

The table below shows the annual total liabilities of Arvee Laboratories (India) Limited from 2013 to 2025.

Year Total Liabilities Change
2025-03-31 Rs68.97 Million
≈ $745.87K
-24.08%
2024-03-31 Rs90.85 Million
≈ $982.46K
-14.48%
2023-03-31 Rs106.23 Million
≈ $1.15 Million
-27.94%
2022-03-31 Rs147.43 Million
≈ $1.59 Million
-24.81%
2021-03-31 Rs196.08 Million
≈ $2.12 Million
+31.28%
2020-03-31 Rs149.36 Million
≈ $1.62 Million
-27.80%
2019-03-31 Rs206.88 Million
≈ $2.24 Million
-30.85%
2018-03-31 Rs299.18 Million
≈ $3.24 Million
-4.96%
2017-03-31 Rs314.81 Million
≈ $3.40 Million
-3.34%
2016-03-31 Rs325.69 Million
≈ $3.52 Million
+32.32%
2015-03-31 Rs246.14 Million
≈ $2.66 Million
+71.40%
2014-03-31 Rs143.60 Million
≈ $1.55 Million
+62.92%
2013-03-31 Rs88.14 Million
≈ $953.24K
--

About Arvee Laboratories (India) Limited

NSE:ARVEE India Specialty Chemicals
Market Cap
$19.64 Million
Rs1.82 Billion INR
Market Cap Rank
#25195 Global
#1401 in India
Share Price
Rs164.83
Change (1 day)
-3.43%
52-Week Range
Rs133.86 - Rs290.78
All Time High
Rs306.70
About

Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company offers polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroi… Read more